Intravitreal anti-VEGF significantly decreased the risk of arterial thromboembolic events by 32% in patients with diabetic macular edema, with the 95% confidence intervals of 6% to 64%; no difference in this risk was detected in patients with neovascular age-related macular degeneration and retinal vein occlusion. This evidence concerns the gene VEGFA and wet macular degeneration.